Vivos Therapeutics, Inc. (VVOS)

The sleep apnea market creates an acute customer problem that Vivos addresses head-on. Millions of people are diagnosed with obstructive sleep apnea each year, but the gold-standard treatment—a CPAP machine that forces air into the airway while you sleep—fails spectacularly in real life. Patients dislike the mask, the noise, the interruption to intimacy and travel. Compliance rates are poor, and many abandon treatment entirely. This compliance gap is where Vivos finds its wedge: a non-surgical, non-invasive oral appliance system that reshapes the airway by gradually expanding the palate and repositioning the lower jaw, allowing patients to sleep normally while their anatomy improves.

The appliance system and how it works

Vivos manufactures custom-fitted oral appliances—physical devices that patients wear at night. The core products are branded as the CARE line: the DNA appliance (the original), along with mRNA and mmRNA variants that evolved from it. Each device sits in the mouth and gently repositions the lower jaw and expands the palate by a few millimetres each month. Over months of wear, the patient’s own bone begins to grow and remodel in response to this gentle pressure, gradually enlarging the airway itself. The mechanism is biological rather than mechanical; the appliance creates the stimulus, but the patient’s body does the actual expansion. This happens entirely during sleep, meaning no waking discomfort and no disruption to daytime life.

The FDA cleared Vivos’ CARE appliances for moderate to severe obstructive sleep apnea in November 2023, a watershed moment because it marked the first oral-device alternative to CPAP cleared for that severity level. Before that clearance, dentists could only prescribe Vivos devices off-label, and insurance coverage was inconsistent. The FDA clearance removed both barriers at once: it validated the approach to regulators and opened insurance reimbursement paths. Medicare approved reimbursement of the CARE appliances in 2024, another milestone that dramatically expands addressable patients.

The business model and its shape

Vivos operates primarily as a business-to-business company selling devices and associated services to dentists. A dentist treats the patient, orders the custom-fitted appliance from Vivos, and handles the month-to-month patient relationship and follow-up. Vivos keeps the high margin; the dentist keeps the patient contact and the lower margin. This model has worked for decades in dental technology generally, and Vivos scaled it to reach more than 1,900 trained dentists worldwide who have treated over 42,000 patients.

However, Vivos is now diversifying this model. The company acquired The Sleep Center of Nevada in 2024 and is actively exploring further acquisitions and collaborations with sleep treatment clinics and centers. This pivot toward direct treatment operations is strategic: it lets the company retain more of the patient interaction and revenue, and it creates recurring revenue from ongoing follow-up care (adjustments, monitoring, managing the transition off the device once airway expansion is complete). A dentist-centric model depends on dentist adoption and referral relationships. A direct-treatment model lets Vivos own the customer relationship entirely and potentially build higher-margin recurring services on top of the core device sale.

Revenue comes from device sales to dentists and, increasingly, from patient treatment and follow-up fees in the company’s own treatment centers. Neither stream is publicly detailed, but both are advancing. The company does not manufacture the appliances in-house; it contracts manufacturing to specialized partners, a typical model in medical devices that keeps capital requirements low.

Pressures and risks

The obvious competition is CPAP itself. Better CPAP machines, improved mask design, and increased patient education may raise compliance and reduce Vivos’ addressable market. However, compliance with CPAP remains stubbornly poor after decades, suggesting that incremental improvements to the machine itself may not move the needle much. Competition also comes from other oral-device manufacturers and from alternative surgical procedures (like positional devices or upper-airway surgery) that can address sleep apnea in patients who decline CPAP or cannot tolerate Vivos treatment. Vivos must defend against the emergence of simpler, cheaper alternative oral devices that might erode its market position.

A deeper risk is insurance and regulatory uncertainty. Vivos’ growth depends entirely on reimbursement coverage and pricing. Medicare’s 2024 approval was a major validation, but Medicare rates are set by the government and may not stay favorable. Private insurance coverage varies widely by plan and geography. Any future changes to what is covered, or at what price, directly affect how many patients can afford treatment and thus how many dentists recommend the device.

The acquisition and direct-treatment strategy carries operational risk. Running sleep centers is different from making devices. The company is new to that business and will need to hire, train, and manage clinical staff at scale. The integration of an acquired center (The Sleep Center of Nevada) will be the first test of whether this model actually works as intended.

Finally, like all medical device companies, Vivos is exposed to the possibility of adverse events, product liability, or regulatory action if the appliances fail to deliver results in real-world use, or if complications emerge. The company mitigates this with postmarket studies and close monitoring, but the risk is inherent in any treatment device.

Research and outlook

Anyone considering Vivos as an investment should start with the company’s 10-K filing (SEC CIK 0001716166), which breaks revenue by customer type (dentists vs. treatment centers) and geography and details the company’s views on key risks. Earnings calls are the place to watch for metrics that matter: the pace of new dentist enrollments, the revenue mix between device sales and treatment center earnings, insurance coverage expansions, and any color on the acquisition pipeline.

The fundamental question is whether the company can grow the direct-treatment business without cannibalizing dentist relationships, and whether direct treatment can eventually become a higher-margin driver than selling devices to dentists. Another critical question is reimbursement: continued expansion of insurance and Medicare coverage is essential to sustained growth. And the larger strategic question is whether Vivos can scale beyond sleep apnea—the company has discussed potential use in other breathing and palatal indications—or whether it remains a focused single-indication business. The market for oral appliances in sleep apnea is substantial, but it is not infinite, and the company will need to demonstrate a path to further growth.